Singh, Nathan http://orcid.org/0000-0002-0350-7574
Frey, Noelle V.
Engels, Boris
Barrett, David M.
Shestova, Olga
Ravikumar, Pranali
Cummins, Katherine D. http://orcid.org/0000-0001-9041-0828
Lee, Yong Gu
Pajarillo, Raymone
Chun, Inkook
Shyu, Amy http://orcid.org/0000-0001-6039-0408
Highfill, Steven L.
Price, Andrew
Zhao, Linlin
Peng, Liaomin
Granda, Brian
Ramones, Melissa
Lu, Xueqing Maggie
Christian, David A.
Perazzelli, Jessica
Lacey, Simon F.
Roy, Nathan H.
Burkhardt, Janis K. http://orcid.org/0000-0002-8176-1375
Colomb, Florent
Damra, Mohammad
Abdel-Mohsen, Mohamed
Liu, Ting
Liu, Dongfang http://orcid.org/0000-0002-7295-8088
Standley, Daron M.
Young, Regina M.
Brogdon, Jennifer L.
Grupp, Stephan A. http://orcid.org/0000-0001-8030-7595
June, Carl H. http://orcid.org/0000-0003-0241-3557
Maude, Shannon L.
Gill, Saar
Ruella, Marco http://orcid.org/0000-0003-4301-5811
Funding for this research was provided by:
Society for Immunotherapy of Cancer
Society for Immunotherapy of Cancer Breakthrough Bike Challenge
EIF | Stand Up To Cancer (SU2C-AACR-IRG 12-17)
Cancer Research Institute
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R01GM104867)
Emily Whitehead Foundation CHOP Immunotherapy Frontier Program V Foundation Curing Kids Cancer
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P01CA214278, R01CA226983, K08CA194256, K99CA212302, R00CA212302)
University of Pennsylvania-Novartis Alliance
American Society of Hematology
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL125018)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI124769, AI29594, AI30197)
Japan Agency for Medical Research and Development (P20am0101108)
Article History
Received: 14 June 2019
Accepted: 18 March 2021
First Online: 22 April 2021
Competing interests
: M.R. and S.G. hold patents related to CART22. C.H.J. has received grant support from Novartis and has patents related to CAR therapy with royalties paid from Novartis to the University of Pennsylvania. C.H.J. is also a scientific founder and holds equity in Tmunity Therapeutics. S.A.G. has received support from Novartis, Servier and Kite and serves as a consultant, member of the scientific advisory board or study steering committee for Novartis, Cellectis, Adaptimmune, Eureka, TCR2, Juno, GlaxoSmithKline, Vertex, Cure Genetics, Humanigen and Roche. B.E., L.Z., L.P., A.P., B.G., M. Ramones and J.B. are employees of Novartis. S.F.L. has received grant support from Novartis, Tmunity and Cabaletta and has patents related to CAR therapy with royalties paid from Novartis to the University of Pennsylvania; he has acted as a consultant for Kite/Gilead. S.L.M. has served as a member of advisory boards or steering committees for Novartis and Kite. All other authors declare no competing interests.